Drug Profile
MK 1006
Alternative Names: MK1006Latest Information Update: 17 Oct 2012
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Antihyperglycaemics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 17 Oct 2012 No development reported - Phase-I for Type-2 diabetes mellitus in Japan (PO)
- 17 Oct 2012 No development reported - Phase-I for Type-2 diabetes mellitus in USA (PO)